A Phase 2 Study of MEK 1/2 Inhibitor Trametinib in Combination With AKT Inhibitor GSK2141795 in Acute Myeloid Leukemia (AML) With RAS Mutations
Phase of Trial: Phase II
Latest Information Update: 09 Apr 2018
Price : $35 *
At a glance
- Drugs Trametinib (Primary) ; Uprosertib (Primary)
- Indications Acute myeloid leukaemia; Acute myelomonocytic leukaemia
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 04 Apr 2018 Status changed from active, no longer recruiting to discontinued due to lack of efficacy.
- 02 Jun 2016 Status changed from recruiting to active, no longer recruiting.